ERBB2 and neoplasm: In carefully designed dose escalation trials conducted without and with lymphodepletion, anti-HER2 CAR T cells elicited no off-tumor, on-target toxicity but resulted in clinically significant responses including a complete response in a patient with metastatic rhabdomyosarcoma (112, 113).